Last checked at 13 Mar 2017 07:00
Shield Therapeutics plc
("Shield" or the "Group")
Notice of Results
London, UK, 13 March 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on the development and commercialisation of late-stage pharmaceuticals that address unmet medical needs in secondary care, announces it will report its audited results for the year ended 31 December 2016 on Tuesday 4 April 2017.
CEO, Carl Sterritt, and members of the management team will host a presentation and live conference call for analysts at 9.30am BST on the morning of the results in the Guildhall Room at 85 Gresham Street, London, EC2V 7NQ.
- Ends -
For further information please contact:
Shield Therapeutics plc | +44 (0)20 7186 8500 |
Carl Sterritt, Chief Executive Officer
| |
Nominated Adviser and Broker Liberum Capital Limited Christopher Britton/Steve Pearce
| +44 (0)20 3100 2222 |
Financial PR Advisor Consilium Strategic Communications | +44 (0)20 3709 5700 shieldtherapeutics@consilium-comms.com |
Mary-Jane Elliott/Matthew Neal |
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until 2034. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.